Shares of Zydus Lifesciences Ltd were trading in the green and 2% higher on 31 July after the company announced receiving approval from the Mexican regulator to commercialise Mamitra, a Trastuzumab biosimilar used to treat various types of cancer.

In its regulatory filing, the company said that after receiving approval from the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) for Mamitra, the drug will be marketed in different strengths of 150 mg and 440 mg. 

The drug is used to treat breast cancer and advanced gastric cancer. The company claims that colorectal tumours and prostate cancer are no longer the most common cancers detected in Mexico. Instead, it is breast cancer.

Dr Sharvil Patel, Managing Director of Zydus Lifesciences, said, “The approval of Mamitra in Mexico allows us to expand the reach of our biosimilar portfolio to newer markets and enable access to affordable life-saving therapies, particularly in oncology.”

In 2016, the Zydus Research Centre (ZRC) research team developed an internal biosimilar to trastuzumab, which was marketed as Vivitra in India. According to the company, the therapy has been used to treat almost one lakh people since then.

At 2:16 pm, the shares of Zydus Lifesciences were trading 2.35% higher at Rs 1,248 on NSE.

Tired of missing hot stocks? Unicorn Signals provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!